What YZR Capital does

YZR Capital is a Munich-based, founder-led venture capital firm that invests in early-stage European HealthTech companies from pre-Seed through opportunistic Series B. The firm is structured as YZR Capital GmbH in Germany and is co-founded and managed by Prof. Dr. Reinhard Meier, a physician-turned-entrepreneur who previously co-founded and sold telemedicine platform TeleClinic.com to a public company in 2020, and Markus Feuerecker, a former Vice-President at DPE Deutsche Private Equity and Senior Investment Manager at EMERAM Capital Partners. The team is supplemented by six Senior Advisors with operating backgrounds across national health insurance, hospital groups, M&A law, and digital platforms, plus two Investors. YZR Capital deploys a ~€100 million fund backed by institutional LPs including the European Investment Fund, Beiersdorf, Bertelsmann Investments, KfW/Wachstumsfonds Deutschland, and Sächsische Aufbaubank.

The firm's business model is classic early-stage venture capital: it earns management fees on committed capital and carries a share of fund profits upon successful exits. Differentiators include deep sector specialism in healthcare, hands-on operational support (regulatory navigation, clinical/scientific guidance, go-to-market strategy, talent hiring, international expansion, follow-on fundraising), and a high-conviction thesis targeting category-defining companies across digital health, AI diagnostics, virtual care, synthetic biology, and TechBio. Distribution relies on direct founder outreach, a proprietary annual Pitchbüchel event in Kitzbühel, and a self-serve Typeform pitch portal. The disclosed portfolio of 13+ companies spans at least 10 countries including Austria, France, Netherlands, Poland, Portugal, Spain, Sweden, Ukraine, the UK, and the USA, with notable rounds in Biorce (€43.8M Series A), roclub ($11.7M Series A), Scripta Therapeutics ($12M seed), Dehaze (€3.2M seed), and Scan.com ($12M). The firm also operates the affiliated YZR Foundation, a humanitarian medical aid entity.

Name

YZR Capital

Legal name

YZR Capital GmbH

Website

https://yzr-capital.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

1–10 employees

Short description

YZR Capital is a Munich-based, founder-led venture capital firm deploying an approximately €100M fund into early-stage European HealthTech companies from pre-Seed to Series B, offering sector-specific operational support and serving ambitious healthcare entrepreneurs across digital health, diagnostics, and TechBio.

Ownership category

akta.pro rank

Product category

Venture Capital Fund Management

NAICS

Funds, Trusts, and Other Financial Vehicles (525), Other Financial Investment Activities (5239)

akta.pro primary industry

Sector-Focused Venture Capital (Vertical Specialists) (FSANAAAD)

akta.pro secondary industry

Early-Stage Venture Capital (Series A/B) (FSANAAAB)

Keywords

• Healthtech venture capital
• Early-stage healthcare investing
• Healthcare innovation funding
• European healthtech fund
• Medical technology investment

Headquarters

HQ city

Munich

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

1. Venture Capital Fund Management: YZR Capital generates returns through equity investments in early-stage HealthTech companies across Europe. The firm manages capital for leading institutional and private investors and earns management fees and carried interest from fund performance. They focus on building champions with lasting impact in healthcare innovation.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

YZR Capital is a sector-specialist venture capital firm that manages an approximately €100M fund dedicated to early-stage HealthTech investments across Europe. The firm invests from pre-Seed through Series B in category-defining companies working on digital health, AI-powered diagnostics, virtual care, synthetic biology, and TechBio platforms, providing capital alongside hands-on operational support including regulatory navigation, go-to-market strategy, talent hiring, and international expansion.

Product overview

YZR Capital is a sector-specialist venture capital firm that invests in early-stage HealthTech companies across Europe. Rather than offering a unified product platform, the firm operates as an investment platform providing capital and operational support to portfolio companies. The firm's investment activities span across digital health, AI-powered diagnostics, virtual care, synthetic biology, and TechBio platforms, covering funding stages from (pre-)Seed through Series B. The portfolio includes companies such as dehaze (AI chronic disease detection), roclub (medtech teleoperation), Biorce (AI clinical trials), Scan.com (medical imaging marketplace), Doctor.One (chronic care management), Filu (veterinary clinics), Deepeye Medical (retinal disease AI), DeepLife (cellular digital twins), OpenHealth Technologies (lab data harmonization), Ima Health (medication management), apoQlar (mixed reality surgery), and DaphOS (healthcare resource optimization).

Differentiator

Problem solved

Functional benefit

Products and services

• YZR Capital HealthTech Venture Fund A sector-focused venture capital fund of approximately €100 million that invests in early-stage HealthTech companies across Europe, from pre-Seed through Series B. The fund backs category-defining companies in digital health, AI-powered diagnostics, virtual care, synthetic biology, and TechBio platforms, and provides portfolio companies with capital alongside hands-on operational support including regulatory navigation, go-to-market strategy, talent hiring, and international expansion. Targeted at ambitious European HealthTech founders.
• Pitchbühel Event A unique annual founder-pitching event held in Kitzbühel, Austria, where 20 selected European HealthTech founders pitch their startups during a gondola ride on the Hahnenkamm race course. The event includes networking and relationship-building opportunities with the YZR Capital team and ecosystem partners. Targeted at Pre-Seed/Seed/Series A European HealthTech founders.

Quantifiable outcome

• Multiple portfolio companies achieving successful funding rounds including Biorce's €43.8M Series A (largest in Iberian HealthTech), Dehaze's €3.2M Seed, Roclub's $11.7M Series A
• +1 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Heal Capital: Berlin-based early-stage HealthTech venture capital firm investing across Europe with a sector-specialist model. Closely comparable to YZR on thesis, stage, and geography, with a similarly small core team.
• Earlybird Health: European early-stage HealthTech/biotech fund within the Earlybird Venture Capital platform. Directly comparable on sector focus, stage, and pan-European footprint, though backed by a larger overall platform.
• Nina Capital: Barcelona-based HealthTech-focused seed and early-stage investor. Comparable sector specialization, stage, and European focus, with overlapping portfolio companies (e.g., Ima Health) — making it both peer and co-investor.
• Speedinvest Health: HealthTech vertical within Speedinvest, a large pan-European early-stage fund. Comparable on stage (Seed/Series A) and HealthTech thesis, but operates with substantially more capital and a broader vertical platform.
• AlbionVC: UK-based early-stage venture firm with a dedicated health vertical. Comparable on stage, healthcare focus, and European footprint; YZR has co-invested alongside AlbionVC in Scripta Therapeutics.
• Apollo Health Ventures: Pan-European HealthTech/biotech early-stage firm focused on aging and longevity. Comparable on sector specialization and stage; YZR has co-led rounds with Apollo Health Ventures in Scripta Therapeutics.

Broad incumbents

• Forbion: Large European life sciences and HealthTech investor operating across early to late stages. Comparable on sector but materially larger AUM and broader stage mandate, making it a broad incumbent versus YZR's early-stage specialist focus.
• Sofinnova Partners: Paris-based healthcare-dedicated venture capital firm with multiple strategies across biotech, medtech, and digital health. Comparable on healthcare-only thesis but with a much larger and longer-tenured platform than YZR.

Others

• Wellington Partners:

Regional players

• Redalpine: Pan-European early-stage venture capital firm with a health and digital health thesis, but with a broader sector mandate. An investor on the team member Till Quitzau's CV indicates ecosystem proximity; comparable on stage and European footprint.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/yzr-vc

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments34 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about YZR Capital